Figures
- Homo sapiens proteomics: clinical perspectives

..................................................

Fig. 1. Experimental design of biological samples directly analyzed by MALDI-TOF-MS. 1) Pre-analytical step where the biological samples are processed and deposited on the MALDI target. 2) Complete screening of the samples derived from pathological and healthy subjects using linear MALDI-TOF-MS technology. 3-4) Combined visualization and statistical features for an easy and efficient identification of biomarker candidates. 5) Identification of the new specific disease-targets.

..................................................

Fig. 2. Complete procedure for the identification of the proteins corresponding to the disease-signal, by a RPHPLC- MS separation to collect purified fractions containing the candidate biomarkers. Each purified liquid fraction is spotted on the MALDI target and analyzed in order to select only those with the interest signals. The selected urified liquid fractions, are digested generically with trypsin. Protein identification can be carried out by MALDI-TOF Peptide Mass Fingerprint (PMF) analysis and by LC-ESI-MS/MS
fragmentation analysis.

..................................................

Fig. 3. MALDI-IMS with the direct employment of histological sections of kidney, returning a two dimensional ion density maps of molecules directly from raw tissue sections.